First Time Loading...

Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211

Watchlist Manager
Tibet Rhodiola Pharmaceutical Holding Co Logo
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Watchlist
Price: 38.7 CNY -0.9% Market Closed
Updated: May 14, 2024
Tibet Rhodiola Pharmaceutical Holding Co
/
Income Statement
/
Income from Continuing Operations

Tibet Rhodiola Pharmaceutical Holding Co
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tibet Rhodiola Pharmaceutical Holding Co
Income from Continuing Operations Peer Comparison

Comparables:
1099
601607
600998
C
600511
000963

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Income from Continuing Operations
¥810.2m
CAGR 3-Years
24%
CAGR 5-Years
30%
CAGR 10-Years
42%
Sinopharm Group Co Ltd
HKEX:1099
Income from Continuing Operations
¥15B
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
16%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Income from Continuing Operations
¥5.2B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
7%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Income from Continuing Operations
¥2.2B
CAGR 3-Years
-14%
CAGR 5-Years
9%
CAGR 10-Years
16%
C
China National Medicines Corp Ltd
SSE:600511
Income from Continuing Operations
¥2.3B
CAGR 3-Years
16%
CAGR 5-Years
8%
CAGR 10-Years
19%
Huadong Medicine Co Ltd
SZSE:000963
Income from Continuing Operations
¥2.7B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
14%

See Also

What is Tibet Rhodiola Pharmaceutical Holding Co's Income from Continuing Operations?
Income from Continuing Operations
810.2m CNY

Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Income from Continuing Operations amounts to 810.2m CNY.

What is Tibet Rhodiola Pharmaceutical Holding Co's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
42%

Over the last year, the Income from Continuing Operations growth was 116%. The average annual Income from Continuing Operations growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 24% over the past three years , 30% over the past five years , and 42% over the past ten years .

ALPHA SPREAD
Join more than 137,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.